The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

ConditionsApraxia of Speech Non-fluent Aphasia Primary Progressive Aphasia Primary Progressive Nonfluent Aphasia

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorMayo Clinic

About this trial

The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All enrolled patients must be over the age of 18, speak English as their primary language, and have an informant who can provide an independent evaluation of functioning.

Each new patient must present with a chief complaint of progressive impairment of speech and must have evidence of AOS documented by a speech-language pathologist during routine clinical evaluation.

At study entry, all patients must have speech sufficiently intelligible for a confident diagnosis of AOS, dysarthria, and/or aphasia, and for acoustic analysis.

Disqualifiers

Any patient whose speech is not intelligible enough for confident speech-language diagnosis will be excluded from the study.

All patients with concurrent illnesses that could account for speech deficits (e.g., traumatic brain injury, strokes, developmental syndromes), and patients meeting criteria for another neurodegenerative disease (e.g., Alzheimer's type dementia57), will be excluded.

Patients with aphasia or dysarthria who do not have PAOS, or whose aphasia or dysarthria at study entry is more severe than PAOS, will be excluded.

All women who are pregnant, or post-partum and breast-feeding, will be excluded as they are unable to undergo the required imaging. All women who can become pregnant must have a pregnancy test no more than 48 hours before the DaTscan.

Trial population

Patients that have been diagnosed as having Progressive Apraxia of Speech.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Testing protocol for the study
Diagnostic test
All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.

Treatment groups

47 Participants

are divided into 1 treatment group

Group A: Progressive Apraxia of Speech1 intervention

Trial outcomes

Primary outcomes

Distinguish types of Progressive Apraxia of Speech

Distinguish types of PAOS using the Apraxia of Speech Rating Scale (ASRS)

Time frame

1-2 years after baseline imaging

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mayo Clinic

Lead sponsor

Source ClinicalTrials.gov

Apply now